Adicet Bio raises $80 million to develop cancer cell therapies

Adicet Bio Inc, a biopharmaceutical company focused on the development of cancer therapies using gamma delta T cells, said on Wednesday it raised $80 million in private funding. "This financing will permit Adicet to continue to develop our proprietary technology, to enter the clinic in non-Hodgkin’s lymphoma and to advance our solid tumor programs," Adicet CEO Anil Singhal said.